Introduction
Maintaining the response of first-line therapy is an important objective in m ultiple myeloma (MM), where even the most intensive therapy followed by autologous stem cell transplantation (ASCT) is usually unable to extend progression-free survival (PFS) to beyond 36 months, with the majority of patients eventually experiencing 3 relapse. Two different concepts regarding treatment following the initial induction therapy exist: consolidation versus maintenance therapy. While consolidation therapy typically consists of the application of a short course of treatment with the aim of deepening the response achieved with the initial therapy, i.e. further reducing the number of tumor cells, maintenance therapy is applied for a prolonged period of time with the goal of preventing tumor progression. To date, no clinical trial has specifically compared consolidation versus maintenance approaches to assess the benefit of one approach over the other.
The high efficacy of the three novel agents, thalidomide, bortezomib and lenalidomide, observed in t he front-line and relapse settings has provided the rationale to also test their capacity to maintain the benefits of first-line therapy in order to prolong remission -a period usually devoid of symptoms of the disease and of toxicities of therapy -and importantly, to extend overall survival (OS). However, it should be noted that the achievement of an OS benefit of a m aintenance therapy may be dif ficult when effective salvage treatment is available at relapse. The demonstration of a prolonged time to progression (TTP) seems to be a v alid objective, provided the prolonged time span without progression of disease is associated with better quality of life and evidently of benefit to the patient (1).
The first attempts with maintenance therapy were already undertaken with conventional chemotherapy agents shortly after their effectiveness in MM had been demonstrated (2) (3) (4) . Results of these initial and of later studies (5-9) were unsatisfactory, and so efforts to improve the outcome of maintenance concepts are ongoing. Here we review current results obtained with novel drugs for maintenance treatment. For meta-analysis, randomized controlled trials (RCTs) of patients receiving thalidomide, thalidomide combination, or lenalidomide maintenance therapy were included. Extraction of summary statistics from the published data was performed according to standard methods for survival-type endpoints, with hazard ratios and their confidence intervals as preferred sources for estimation, and logrank p values/event counts as second choice (10) . Standard techniques for meta-analysis (11) were used to calculate the pooled estimates, as incorporated in the software packages METASUB V. 1.1 (idv, Gauting, Germany) and R eview Manager V. 4.2 (Nordic Cochrane Centre, Copenhagen). Both fixed (primarily) and random effects model methodology were applied. All reported p-values result from two-sided versions of the respective tests.
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Chemotherapy, Interferon and Glucocorticosteroids
The first trials designed to prolong the duration of the remission phase and OS simply continued chemotherapy after successful induction treatment with MP (2) (3) (4) . This led Brian Durie on January to a significant prolongation of the duration of remission but not to superior survival, and thus was not pursued further.
Interferon was shown to exert anti-myeloma activity as a single agent in 1979 (12) , and subsequent trials employed interferon for induction and for maintenance therapy.
Individual trials revealed variable results, with significant prolongation of remission duration and also of survival in some, and negative outcomes in other studies. Two meta-analyses, one on individual patient data (5) and the other using published data (6), revealed a s ignificant but limited improvement in both remission duration and survival of about 6 months. Due to toxicity and the inability to select those patients likely to benefit from and tolerate interferon, this concept has, with few exceptions, generally been abandoned.
Glucocorticosteroids have significant activity in m yeloma as single agents (13) and induce additive or synergistic activity in combination with other drugs (14) . Berenson (7) showed a significant increase in rem ission duration and in s urvival with 50 m g prednisone every other day compared to 10 mg every other day, but in another study with single-agent dexamethasone (40 mg d 1-4, q 28 days) no benefit was observed (8) . A comparison of dexamethasone with interferon maintenance treatment showed similar remission durations, but more relapsing patients could be re-induced with melphalan-dexamethasone after interferon maintenance therapy than after dexamethasone (9) . Taken together, the available evidence is insufficient for recommending corticosteroid maintenance therapy.
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Thalidomide
After the demonstration of the limited benefits of interferon (5, 6 ) and corticosteroids (7) (8) (9) as maintenance therapy, thalidomide became the next logical candidate for clinical evaluation. The absence of severe hematotoxicity and its availability as an oral drug were favorable prerequisites for long-term use, but these advantages proved partly abrogated by its specific toxicity profile, in particular neurotoxicity.
Thalidomide as maintenance treatment has mainly been studied in young patients after ASCT.
Three (15, 16, and 22) of the six trials with thalidomide maintenance treatment after ASCT (15-22) used thalidomide only as maintenance treatment. In two studies thalidomide was administered both during the induction and maintenance phases (18, 21), while in the MRC Myeloma IX study (17), approximately half of the patients randomized to thalidomide maintenance treatment had thalidomide during induction therapy (Table 1 ).
In the IFM 99 02 study, patients were randomized after double ASCT to thalidomide plus pamidronate, to pamidronate alone, or to control (15) . A significant improvement in the quality of response was observed in the thalidomide-containing arm, with more patients achieving very good partial response (VGPR) or complete response (CR) compared to the two other groups. Furthermore, an inc reased event-free survival (EFS), as well as improved OS could be s hown, but the benefits of thalidomide maintenance therapy were seen only in patients with less than VGPR after double ASCT, and only in those without del13 and high ß -2 microglobulin. Survival after relapse did no t vary between the three study arms. After long-term follow-up of 7 patients with cytogenetics available (thereby excluding 90 patients) (20), the initially observed survival benefit was not maintained, with an estimated 5-year OS rate of 74% in the thalidomide-pamidronate arm and 70% in both control groups (P=0.53).
In the Australian trial (16) , patients were randomized after single ASCT to either thalidomide maintenance treatment in combination with alternate-day prednisolone or to prednisolone alone. Treatment with thalidomide was planned for 12 months, but alternate-day prednisolone could be continued in both arms until progression. Fiftyeight percent of the patients initially randomized to thalidomide remained on maintenance therapy. The thalidomide-containing treatment resulted in a higher rate of VGPR, increased PFS and increased OS. OS after relapse did not differ between the two groups The MRC myeloma IX study consists of two trials, one in y ounger and t he other in older patients (17). In the entire patient group, no difference was noted in the percentage of patients that upgraded response status. In the transplant study thalidomide maintenance treatment resulted in increased PFS, while for the survival rate at 3 years no improvement was obtained. Survival regarding FISH-defined cytogenetic risk groups was assessed in both patient cohorts combined. In patients with favorable FISH, PFS was significantly prolonged with thalidomide maintenance therapy (P= 0.004) with no ap parent improvement yet of OS (P= 0.48), but survival curves indicate a likely late survival benefit after longer follow up. Patients with adverse FISH [t (4; 14), t (14; 16), t (14; 20), del17p, del (1p32), gain (1q21)] showed similar PFS (9 vs. 12 months, P= 0.48), but worse OS (P= 0.009) with thalidomide maintenance (17).
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Barlogie and colleagues compared thalidomide in c ombination with total therapy II (TT2) and pos t-transplant chemotherapy to the same chemotherapy without thalidomide (18-20). Maintenance thalidomide was given until disease progression (PD) or intolerance. After a median follow-up of 40 months, both a significantly higher CR rate and EFS at 4 years were noted, while for OS no difference was observed.
After relapse, survival was significantly shorter in patients pre-exposed to thalidomide (20) . A re-analysis after a median follow-up of 6 years revealed a survival estimate of 57% in the experimental arm and of 44% (P=0.09) in the control arm (19). EFS was superior in the thalidomide arm, with a median of 6.0 years versus 4.1 years (P=0.001). Patients with metaphase-defined cytogenetic risk factors had significantly longer survival (OS at 5-years (56% vs. 43%, P=0.02). The cumulative frequency of CR was significantly higher in the thalidomide group, regardless of cytogenetic status. Segregation of survival curves became evident 2-3 y ears after the start of therapy in patients with cytogenetic abnormalities, and after 7 years in those without.
Survival after relapse was significantly longer in control patients without cytogenetic abnormalities (5-year OS estimate: 25% v s. 6%, P= 0.04), but was similar between both treated and untreated patients with cytogenetic risk factors (5-year OS estimate: 29% vs. 33%, P=0.99). A further re-analysis after an additional 38 months of followup, for a total follow-up of 87 months, finally showed OS to be significantly extended in the thalidomide arm (P= 0.04), despite discontinuation of thalidomide for toxicity and other reasons in nearly 80% within 2 years (20).
In the HOVON-50 study (20), patients were randomized to either TAD followed by single or double ASCT and maintenance therapy with low-dose thalidomide (50 mg/day), or to VAD followed by single or double ASCT and maintenance treatment with interferon alpha. Maintenance treatment was given until progression. Patients randomized to thalidomide maintenance achieved a significantly higher VGPR rate, longer EFS and a tendency for improved OS. Survival after relapse was significantly shorter in patients exposed to thalidomide induction and maintenance treatment. Fifty percent of patients developed peripheral neuropathy (PNP), and 58% ha d dose reductions or discontinued thalidomide. Our meta-analysis of the published trial results revealed a significant reduction of the risk for progression (HR:0.65, 95% C I: 0.59, 0.72) with thalidomide maintenance therapy. Outcome did n ot differ between trials that used thalidomide during the maintenance phase only and those that used thalidomide both for induction and maintenance treatment. For OS a m ajor effect variability between trials was noted (test for heterogeneity P= 0.03). Therefore, the positive result for overall effect (HR: 0.84, 95%CI: 0.73 -0.97, P=0.01) must be interpreted with caution. The most likely explanation for this heterogeneity is the inclusion of elderly patients in the MRC and GEMSG trial, where no improvement in OS was noted. The variability for OS in the thalidomide trials might also be explained by the availability of novel agents at relapse, which differed among countries and for different time periods.
The improvement in qu ality of response with thalidomide maintenance reported in most trials (15, 16, 18 , 21, and 22) supports a consolidation in addition to a maintenance effect of thalidomide. Patients with unfavorable cytogenetics defined by FISH did no t benefit from thalidomide maintenance in the IFM and the MRC IX studies, in fact in the latter trial survival was significantly shorter in patients with FISH defined adverse cytogenetics (17). These observations and evidence from other studies suggest that patients without FISH-defined cytogenetic risk factors are more likely to benefit from thalidomide maintenance treatment while those with a FISHdefined high-risk profile likely should not be offered this form of maintenance therapy.
In Arkansas, genetic risk is defined both by metaphase cytogenetics and more recently by gene expression profiling (24). Patients defined this way are only party comparable to FISH-defined high-risk patients, which may explain the greater benefit of thalidomide in the Arkansas high-risk grou
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An interesting phenomenon of different outcomes at different periods of trial maturity was noted in the TT2, the IFM and the MRC IX trials. In the TT2 study, OS was not different after 42 months of follow up, became superior in patients with metaphasedefined adverse cytogenetics after 70 m onths, and was significantly longer in t he total group of patients after 87 months of follow-up (20). In the IFM study, an analysis of 88% o f patients initially enrolled revealed an inverse pattern, with a s ignificant advantage seen at first analysis that was lost at later follow-up (20). The pattern of increasing benefit in the TT2 trial indicates the favorable impact of thalidomide maintenance primarily in good -risk patients, because an ef fect in high-risk patients should have become evident much earlier due to the reduced survival generally seen in high-risk disease. This notion is also supported by the MRC IX trial, which indicates a t endency for improved survival in FISH-favorable patients after long follow-up. The conversion of survival curves after long-standing disease in t he IFM trial does not support this explanation, and may reflect a significant influence of salvage therapy in good-risk patients on OS.
In two trials exploring the role of thalidomide maintenance treatment after conventional therapy (17, 25), approximately 50% of patients had already been exposed to thalidomide-containing induction regimens. In the CEMSG trial (25) patients were randomized to thalidomide pus interferon or to interferon maintenance therapy. The thalidomide-containing combination induced a s ignificant increase in PFS (27.7 vs. 13.2 months, P=0.0068), but OS was similar between the two groups (52.6 vs. 51.4 months, P=0.81) and did not differ between patients aged 75 years or older and younger patients (P=0.39). Survival after disease progression tended to be shorter in patients exposed to thalidomide-interferon maintenance therapy (P=0.056).
Patients receiving thalidomide-interferon had m ore PNP (69% v s. 38%, P= 0.0015), constipation (44% vs. 19%, P= 0.0004), skin toxicity (33% vs. 11%, P= 0.0041) and elevated creatinine (13% vs. 5%, P=0.026). In the MRC myeloma IX study, PFS was significantly, but only moderately increased with thalidomide maintenance (11 vs. 9 months, P=0.014), while for OS no difference (38 vs. 39 months, P=0.995) was noted (17). Survival after relapse was shorter in thalidomide exposed patients, but the difference did no t reach statistical significance (21 vs. 26 m onths, P= 0.25). When novel drugs were selected for salvage therapy after relapse, survival was improved, a finding which was also noted in younger patients (17).
Seven randomized trials have compared MPT with MP in elderly patients (26-33), and in f our of them thalidomide was given after MPT as maintenance (26, 30-32).
There was significant heterogeneity in the design of these studies, with differences in the dose, schedule, and duration of MPT therapy (Table 2) The optimal dose of thalidomide should be t he minimal effective dose that is associated with superior tolerance and least toxicity. Since its introduction, the doses of thalidomide have continuously been decreased from the initial 400 mg/day (18) to as little as 50 mg/day in the HOVON-50 study (30). As the results have been similar 13 in most trials, a dose of 50 to 100 mg/day may be recommended as an appropriate dose.
The median duration of thalidomide treatment varied between 7 months in the MRC IX trial (17), 13.2 months in the CEMSG study (25), 15 months in the IFM trial (15) , and almost 24 m onths in t he HOVON study (30), which used the lowest dose of thalidomide and in which 47% of patients were still on therapy at that time point.
Recommending a specific length of thalidomide therapy is difficult, but in a multivariate analysis, no impact of treatment duration was noted (19). Limiting the duration of thalidomide exposure should reduce the risk of severe side effects, particularly PNP, the most relevant toxicity (15, 16) . Other side effects are constipation, fatigue, mood disturbances, and, particularly in elderly patients, arrhythmias, bradycardia and thromboembolic complications.
Lenalidomide
Lenalidomide is an attractive drug for maintenance therapy with the advantage of oral 14 The CALGB 100104 study randomized 460 patients after ASCT to lenalidomide maintenance therapy or to placebo (38). The induction regimen before ASCT was not specified and patients were stratified according to previous thalidomide or lenalidomide exposure during induction therapy and to ß-2 microglobulin levels. After a median follow-up of 28 months from ASCT, median TTP was 48 months in t he lenalidomide maintenance, and 30.9 months in the placebo group (HR: 0.39, 95% CI, 0.27 -0.56, P<0.0001) ( Table 3 ). Lenalidomide maintenance treatment was equally effective in patients with high or low ß-2 microglobulin levels, and in those previously exposed to thalidomide or lenalidomide therapy. Overall survival was significantly increased with lenalidomide maintenance therapy despite a cross-over to lenalidomide by some of the placebo patients after unblinding of the study in January Patients on lena lidomide maintenance therapy had an increased incidence of secondary malignancies (26 vs. 6 cases). Common toxicities were relatively low with 21% of patients on lenalidomide and 15% on plac ebo discontinuing therapy due to toxicity.
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The results of the lenalidomide maintenance studies require longer follow-up to confirm whether the positive finding in t he CALGB study will prove robust, and whether similar improvements will be seen in the IFM study, which differed with respect to the patient population and treatment. If good-risk patients benefit more from lenalidomide maintenance, survival curves should start to diverge after prolonged follow-up.
In any event, a time span without progression of disease usually is associated with better quality of life (1), and hence, is of substantial benefit to the patient.
Lenalidomide maintenance therapy was well tolerated with almost negligible hematotoxicity, no neurotoxicity, and no increase in thromboembolic complications or infections. The observation of an increased occurrence of second primary malignancies (SPM), however, is notable. The incidence of SPM was slightly higher in the IFM trial, where a proportion of patients had been exposed to induction therapy incorporating DCEP, which contains drugs of known leukemogenic potential. Further studies are needed to evaluate the true risk of this complication, to identify risk factors for its development, and hopefully, to develop strategies for the prevention of SPMs. Before more information is available, a firm recommendation cannot be made.
Physicians and patients must weigh the benefits of lenalidomide maintenance therapy against the low but relevant risk of SPM.
In elderly patients, a phase 2 trial with MPR was the forerunner for the MM-015 trial years old). With a median follow-up of 41 months for OS, the OS rate at four years was similar between the three groups (58%-59%). Grade 3 and 4 neutropenia and thrombocytopenia were significantly more frequent in the MPR arm, and prophylactic G-CSF was administered to 49% of patients in the MPR-R group compared to 29% of patients in the MP arm; platelet transfusions were administered to 6% and 5% of patients, respectively (42). Overall 20% of patients in the MPR-R, 16% in the MPR, and 8% in the MP group discontinued therapy due to adverse events. Notably, the rate of discontinuation was higher in pat ients > 75 years old than in t hose 65-75 years old (22% vs. 12%, respectively), indicating that treatment tolerance is reduced in the very elderly population. A subsequent analysis revealed an increased rate of secondary malignancies in t he MPR-R and MPR compared to the MP group (12 (8.0%), 10 (6.6%), and 4 (2.6%) patients respectively).
Our meta-analysis of the published results of the three lenalidomide maintenance studies, which included a total of 1380 patients, revealed a 65% risk reduction for progression for patients on lenalidomide maintenance therapy ( Figure 1C Table 4 ).
The induction therapy consisted of one 6-week cycle with biweekly bortezomib followed by five 5-week cycles with weekly bortezomib to reduce toxic side effects.
After induction, 178 patients were randomized to either VT or VP maintenance therapy. Bortezomib maintenance was administered every three months using the A GIMEMA (45) study randomized 511 patients to either nine 6-week cycles of VMPT induction therapy followed by VT maintenance or to nine 6-week cycles of VMP induction treatment. After inclusion of 139 patients, the biweekly administration of bortezomib was reduced to a o nce-weekly schedule to enhance the tolerance of bortezomib, and both the VMPT and the VMP schedules were changed to nine 5-week cycles. Patients on VMPT followed by VT maintenance achieved a higher rate of CR and ≥ VGPR (38% vs. 24%, P<0.001, and 59% v s. 50%, P=0.03 respectively) and had both a significantly higher rate of PFS at 3-years (56% vs. 41%, P= 0.008) and a longer time to next treatment (72% vs. 60%, P=0.007). The OS rate at 3-years, was similar in both groups (89% vs. 87%, P= 0.77). Patients in the VMPT arm experienced more grade 3 and 4 ne utropenia (38% vs. 28%, P = 0.02), thromboembolic events (5% vs. 2%, P=0.08), and cardiologic side effects (10% vs.
5%, P=0.04). However, the evaluation of the benefit of maintenance treatment in this trial is difficult since different induction treatments had been used in the two arms.
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Combining two drugs with significant neurotoxic potential poses the risk of substantial toxicity, but contrary to such concerns, clinical experience shows an acceptable tolerance if a 'low-dose intensity' concept is used. Thalidomide was administered at a daily dose of 50 mg continuously, and the dose intensity for bortezomib was 6 doses over three months in the Italian study and 4 d oses over the same period in t he Spanish study. VT maintenance treatment resulted in a low rate of grade 1-2 neurotoxicity and a low discontinuation rate, as well as a tendency for increased PFS in comparison to bortezomib plus prednisone in the PETHEMA study (44). In the GIMEMA trial (45), a tendency for an increase in PFS (P=0.07) compared to control was observed. OS did not differ between VT and VP maintenance therapy in the Spanish study, and in the Italian trial, no difference in the survival rates at 3 years were noted between patients receiving VT maintenance therapy or those randomized to the control arm (88.1% vs. 89.2%, P=0.9).
The joint HOVON/GMMG trial randomized 613 patients to bortezomib-doxorubicindexamethasone (PAD) or VAD induction therapy followed by single or double ASCT (46). Patients started on PAD received bortezomib maintenance (1.3 mg/m 2 , biweekly for two years) and those randomized to VAD were treated with thalidomide maintenance therapy (50 mg, daily for two years). After a median follow-up of 40 months, the nCR/CR rate was 38% in t he VAD/ASCT/thalidomide arm and 50% in the PAD/ASCT/bortezomib arm; the respective rates for ≥ VGPR were 61% and 75%.
PFS and OS were significantly longer in the PAD/ASCT/bortezomib-treated patients (HR: 0.81, P=0.047, and HR: 0.74, P=0.048, respectively), with PFS and OS rates at 36 months of 48% and 78% in the VAD/ASCT/thalidomide group and 42% and 71% 21 in the PAD/ASCT/bortezomib/group, respectively. 67% of patients in t he VAD/ASCT/thalidomide arm and 57% in the PAD/ASCT/bortezomib arm started maintenance therapy; 64% of those on thalidomide maintenance discontinued maintenance therapy because of PD (31%), toxicity (31%) and ot her reasons (2%).
In the bortezomib arm, 47% discontinued maintenance because of PD (29%), toxicity (9%), or other reasons (9%) and 27% re quired dose reductions. In essence, the PAD/ASCT/bortezomib protocol was in all study objectives superior to the VAD/ASCT/thalidomide regimen, including patients with renal impairment (47) and with adverse FISH-determined cytogenetics (t [4; 14] , amplification of 1q21, and del 17p) (48). The study showed that bortezomib maintenance therapy can be tolerated for up to two years, but the design of the study does not allow a clear dissection of the role of bortezomib maintenance therapy.
As several questions regarding the optimal use of bortezomib, in p articular scheduling, dosing, duration of therapy, combination with other drugs, remain unresolved, specific recommendations cannot be made for bortezomib maintenance therapy at this point of time.
Considerations for clinical practice
Presently, in most countries none of the novel drugs evaluated for maintenance therapy is approved for this indication. Nevertheless, patients will find access to the available information and will query their treating physicians about possible treatment options after induction therapy besides a wait and see strategy, which remains a valuable alternative. Based on present scientific evidence (Table 5) , thalidomide maintenance treatment after ASCT is a p ossible option that increases PFS and, albeit to a les ser degree, OS. Thalidomide maintenance should not be of fered to 22 patients with FISH-defined poor-risk cytogenetics, because those patients had inferior outcome with thalidomide maintenance therapy compared to controls. The lowest dose shown to be ac tive is 50 mg daily, and t he duration of therapy should potentially be limited to one year or less in order to limit the risk of significant toxicity.
For elderly patients, the situation is less clear. In both studies conducted so far, roughly half of the patients had already been exposed to thalidomide during induction therapy. Results showed a s ignificant increase in PF S, but not in O S. Thalidomide maintenance therapy in elderly patients with favorable cytogenetics therefore is also a valuable option, but thalidomide tolerance decreases with increasing age. Results of some studies suggest that thalidomide maintenance should preferentially be considered in pat ients who have not been exposed to thalidomide during induction therapy, but this observation was not confirmed in the MRC trial (17).
Lenalidomide after ASCT is associated with a s ignificantly increased PFS (38, 39), and in one study (38) with a significant survival benefit. It is well tolerated and active Data on s ingle-agent bortezomib maintenance treatment are available only in patients who had already been exposed to bortezomib during induction therapy (46).
Twice-weekly bortezomib maintenance therapy is feasible and can be tolerated for up to two years, but dose reductions may be necessary in up to one third of patients.
While a significant benefit of bortezomib maintenance therapy is likely, the design of the study allows only the conclusion that a bortezomib-based induction regimen followed by ASCT and bortezomib maintenance is superior to VAD induction followed by ASCT and thalidomide maintenance therapy. Bortezomib maintenance in combination with thalidomide has been s hown to yield superior PFS compared to control (45) or ( although not statistically significant) compared to bortezomib plus prednisone in elder ly patients (44). Further studies, particularly in pat ients not previously exposed to these drugs during induction phase, are warranted.
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